SRT3 Share Price Performance
€0
-240.20 (-100.00%)
Price €0
Fair Value€260.05
Share Pricen/a
Sartorius Aktiengesellschaft Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
SRT3 Community Narratives
AN
Fair Value €260.05 10.3% undervalued intrinsic discount
Advanced Biologic Adoption Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value €310 24.7% undervalued intrinsic discount
Cell And Gene Therapies Will Expand Secular Bioproduction
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value €191.2 22.0% overvalued intrinsic discount
Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins
Key Takeaways Rising protectionism, regulatory changes, and industry consolidation threaten Sartorius' revenue growth, margins, and market reach through suppressed pricing power and supply chain fragmentation. Technological disruption and intensifying lower-cost competition risk obsolescence of core products, pressuring innovation, margin expansion, and returns on research investments.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€191.2
22.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
7.46%
Future PE
50.19x
Price in 2028
€0
Cell And Gene Therapies Will Expand Secular Bioproduction
Key Takeaways Expanding innovation in bioprocessing and preclinical services positions Sartorius to capture outsized growth from next-generation therapies and the shift from animal testing. Strong recurring revenue, rising emerging market presence, and operational leverage signal sustained earnings and margin gains beyond current market expectations.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€310
24.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.89% p.a.
Profit Margin
11.77%
Future PE
45.43x
Price in 2028
€369.66
Advanced Biologic Adoption Will Expand Global Reach
Key Takeaways Strong product innovation and rising demand for advanced biologic drugs are strengthening Sartorius' recurring revenues, margins, and competitive position. Expanding global healthcare access and consumables growth diversify revenue streams and reduce cyclicality, supporting sustained and higher-quality earnings.Read more
46
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
€260.05
10.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
9.16% p.a.
Profit Margin
8.78%
Future PE
53.51x
Price in 2028
€309.66
Trending Discussion
Recently Updated Narratives
AN
Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins
Fair Value: €191.2 22.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cell And Gene Therapies Will Expand Secular Bioproduction
Fair Value: €310 24.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advanced Biologic Adoption Will Expand Global Reach
Fair Value: €260.05 10.3% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sartorius Aktiengesellschaft Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 23, 2026
- 2.24
- 46.26%
- 4.38%
- 105.4%
About SRT3
- Founded
- 1870
- Employees
- 13671
- CEO
- WebsiteView website
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
